
Incyte Corporation
INCYHealthcare|Biotechnology|US
$119.65
+1.64 (+1.39%)
DCF Value
$113.08
Tangible Book / Share
$26.60
Graham Number
$35.21
Cash / Share
$18.97
Next Earnings Report
Feb 9, 2027
EPS est. $1.90 · Revenue est. $1.55B
Financing Filings (last 12 months)
0
No shelf registrations or offering prospectuses filed.
Upcoming Data Readouts (108)
Nov 2026
Est. completion
P2Moderate to Severe Asthma
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
NCT05851443n=247
Dec 2026
Est. completion
P2Hodgkin Lymphoma
Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
NCT05723055n=9
Dec 2026
Est. completion
P2TNBC - Triple-Negative Breast Cancer
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
NCT05491226n=35
Dec 2026
Est. completion
P1Acute Myeloid Leukemia
Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT
NCT06551584n=24
Dec 2026
Est. completion
P1Hidradenitis Suppurativa
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT07049575n=24
Dec 2026
Est. completion
P3Hidradenitis Suppurativa (HS)
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06212999n=617
Dec 2026
Est. completion
P1Acute Myeloid Leukemia
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
NCT04659616n=32
Dec 2026
Est. completion
P2Advanced Pancreatic Carcinoma
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
NCT06906562n=40
Dec 2026
Est. completion
Dec 2026
Est. completion
Early P1Lymphoma, B-Cell
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
NCT04161248n=40
Jan 2027
Est. completion
P2Large B-cell Lymphoma
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
NCT06760156n=28
Jan 2027
Est. completion
P1Solid Tumors
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06179160n=710
Jan 2027
Est. completion
P2Splenomegaly
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
NCT06345495n=30
Jan 2027
Est. completion
P1Myelofibrosis Due to and Following Polycythemia Vera
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
NCT05714072n=18
Jan 2027
Est. completion
P1Chronic Lymphocytic Leukemia
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
NCT05943496n=27
Jan 2027
Est. completion
P1Renal Impairment
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease
NCT07559396n=16
Jan 2027
Est. completion
P1P2Chronic Graft-versus-host-disease
A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD
NCT06843408n=32
Jan 2027
Est. completion
P2Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
NCT06056895n=12
Feb 2027
Est. completion
P2Diffuse Large B Cell Lymphoma
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
NCT05757219n=27
Feb 2027
Est. completion
P2Non-Hodgkin Lymphoma
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
NCT05583071n=20
Awaiting Results (31)
Trials past primary completion date but still active — data readout may be imminent.
Nov 2026
P1
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants
NCT07448155Nov 2026
P2
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
NCT04509700Oct 2026
P3
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965Oct 2026
P3
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
NCT06516952Oct 2026
P3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
NCT06958211Oct 2026
P3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225Oct 2026
P2
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
NCT06388564Sep 2026
P2P3
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
NCT03117751Sep 2026
P3
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
NCT04824092Aug 2026
P3
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618Recent Press Releases
2026 Incyte Ingenuity Awards in GVHD™ Awarded to University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute
Nov 6, 2026 · Business Wire
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
Oct 29, 2026 · Business Wire
Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
Oct 26, 2026 · Business Wire
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Oct 24, 2026 · Business Wire
Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Oct 24, 2026 · Business Wire
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Oct 24, 2026 · Globe News Wire
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
Oct 18, 2026 · Business Wire
Incyte Honors the 2026 MPN Heroes®, Celebrating Champions of the Myeloproliferative Neoplasm (MPN) Community
Oct 13, 2026 · Business Wire
Incyte to Report Third Quarter Financial Results
Oct 8, 2026 · Business Wire
Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
Oct 6, 2026 · GlobeNewsWire
SEC Filings (49)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Oct 29, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Oct 29, 2026 | 8-K | Material event | DocumentIndex |
| Aug 31, 2026 | 8-K | Material event | DocumentIndex |
| Jul 28, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Jul 28, 2026 | 8-K | Material event | DocumentIndex |
| Jul 6, 2026 | 8-K | Material event | DocumentIndex |
| Jun 22, 2026 | 8-K | Material event | DocumentIndex |
| Jun 9, 2026 | 8-K | Material event | DocumentIndex |
| Jun 8, 2026 | 8-K | Material event | DocumentIndex |
| May 27, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| May 14, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| May 11, 2026 | SC 13D/A | Activist / 5%+ stake | DocumentIndex |
| Apr 30, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 28, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 28, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 28, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Apr 28, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Apr 28, 2026 | 8-K | Material event | DocumentIndex |
| Mar 30, 2026 | 8-K | Material event | DocumentIndex |
| Mar 27, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Mar 26, 2026 | 8-K | Material event | DocumentIndex |
| Mar 6, 2026 | 8-K | Material event | DocumentIndex |
| Feb 10, 2026 | SC 13D/A | Activist / 5%+ stake | DocumentIndex |
| Feb 10, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 10, 2026 | 8-K | Material event | DocumentIndex |
| Dec 12, 2025 | 8-K | Material event | DocumentIndex |
| Nov 10, 2025 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Nov 7, 2025 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Oct 28, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Oct 28, 2025 | 8-K | Material event | DocumentIndex |
| Oct 17, 2025 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Oct 3, 2025 | 8-K | Material event | DocumentIndex |
| Aug 7, 2025 | 8-K | Material event | DocumentIndex |
| Jul 29, 2025 | 10-Q | Quarterly report | DocumentIndex |
| Jul 29, 2025 | 8-K | Material event | DocumentIndex |
| Jul 2, 2025 | S-8 | Employee stock plan | DocumentIndex |
| Jun 27, 2025 | 8-K | Material event | DocumentIndex |
| Jun 18, 2025 | S-8 | Employee stock plan | DocumentIndex |
| Jun 18, 2025 | S-8 | Employee stock plan | DocumentIndex |
| Jun 11, 2025 | 8-K | Material event | DocumentIndex |